P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer ; volume:2 ; number:2 ; day:12 ; month:3 ; year:2014 ; pages:1 ; date:3.2014
Journal for ImmunoTherapy of Cancer ; 2, Heft 2 (12.3.2014), 1, 3.2014
- Urheber
-
Jallad, S.
- Beteiligte Personen und Organisationen
-
Thomas, P.
Newport, M.
Kern, F.
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-2-S2-P32
- URN
-
urn:nbn:de:1111-2016072657381
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jallad, S.
- Thomas, P.
- Newport, M.
- Kern, F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
Intravesical Treatments of Bladder Cancer: Review
Protective role of intravesical BCG in COVID-19 severity
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
Intravesical Treatments of Bladder Cancer: Review
Protective role of intravesical BCG in COVID-19 severity
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
Intravesical Treatments of Bladder Cancer: Review
Protective role of intravesical BCG in COVID-19 severity
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’